https://raceoncology.com/category/media-release/page/8/?section=3&sl-year=2018
From 2018 - Race Oncology is pleased to announce the appointment of US-based Dr John Cullity as a non-executive director for Race Oncology. Dr Cullity has previously held senior executive roles with Sanofi-Aventis and ...
https://*********.com.au/race-oncology-agreement-pursue-bisantrene-cancer-drug-licensing/
Looks like the Sanofi connection is probably null and void (but it resulted in JC's 8m (cheap) shares).
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. Originally, the corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index.[2]
So JC must have worked with Sanofi-Aventus between 2004 and 2011, using that association in his CV for the 2018 RAC appointment.
Sounds familiar ?, page-2
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.41 |
Change
0.095(7.22%) |
Mkt cap ! $234.3M | |||
| Open | High | Low | Value | Volume |
| $1.32 | $1.41 | $1.32 | $249.8K | 182.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2826 | $1.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.43 | 40000 | 1 |
View Market Depth
| Last trade - 16.10pm 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.37 |
Change
0.095 ( 6.64 %) |
||||
| Open | High | Low | Volume | ||
| $1.34 | $1.41 | $1.32 | 16145 | ||
| Last updated 15.53pm 10/05/2024 ? | |||||
| RAC (ASX) Chart |